GRM6 Regulatory Sequences for Retinal Cell-Specific Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapeutic vectors lack cell-type specificity, leading to inefficient and costly development processes for targeted gene expression in neural pathways, particularly in the visual pathway.
Innovation Solution
Development of synthetic regulatory sequences, such as the GRM6 regulatory sequence, operatively linked with light-sensitive proteins like ChR2, to achieve high-throughput targeted expression in specific neural cells, including retinal bipolar cells, using recombinant adeno-associated viruses (AAV) for efficient delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If ubiquitous promoters are used for gene expression control, then high expression intensity is achieved, but cell-type specificity is lost
Solution Approach 1:
The patent applies local quality by replacing ubiquitous promoters with cell-type-specific promoters that have different regulatory properties tailored to specific neural cell types. Each promoter is designed with specific transcription factor binding sites that confer cell-type specificity while maintaining appropriate expression levels for that particular cell type, thereby achieving both specificity and functional expression intensity.
Solution Approach 2:
The patent employs parameter changes by systematically varying promoter sequences to alter their regulatory characteristics. Different promoters are engineered with specific combinations of transcription factor binding sites, enhancer elements, and regulatory motifs that change the expression parameters (cell-type specificity, expression level, temporal pattern) to match the requirements of different neural cell types.
2Measurement precision
If regulatory sequence analysis and development for cell-specific promoters is performed, then cell-type specificity is achieved, but the process becomes long, arduous, and expensive
Solution Approach 1:
The patent applies preliminary action by pre-characterizing and pre-validating a library of promoters for their cell-type specificity and expression properties before they are used in therapeutic applications. Promoters are screened and selected in advance based on their ability to drive expression in specific neural cell types, reducing the time needed for validation during actual therapeutic development.
Solution Approach 2:
The patent uses copying by adapting and modifying existing well-characterized promoters rather than creating entirely new regulatory sequences from scratch. Promoters from model organisms or previously studied genes are used as templates and engineered to target specific neural cell types, significantly reducing development time and cost compared to de novo promoter creation.
3Productivity
If existing gene therapeutic vectors are used, then gene delivery is achieved, but cell-type specificity and therapeutic efficacy are insufficient
Solution Approach 1:
The patent applies segmentation by dividing the gene therapy system into separate functional components: cell-type-specific promoters, therapeutic genes, and delivery vectors. This modular approach allows independent optimization of each component, enabling precise control over which cells receive which therapeutic gene, thereby improving both cell-type specificity and therapeutic efficacy.
Solution Approach 2:
The patent employs an intermediary approach by using promoter sequences as mediators between the delivery vector and the therapeutic gene. These promoters act as regulatory intermediaries that control where and when the therapeutic gene is expressed, ensuring that the gene product is produced only in the intended cell type, thus enhancing therapeutic efficacy while minimizing off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves greater than 80% specific expression in target cells, such as retinal ON bipolar cells, while minimizing expression in non-target cells, thereby enhancing therapeutic efficacy for visual disorders like blindness.
Implementation Method 1
a nucleic acid encoding a light-sensitive protein
Data Source
AI summary
Provided herein are compositions and methods for the design of synthetic regulatory sequences and for subsequent modulation of neural pathways.